AR005472A1 - INHIBITORS OF THE HUMAN SOLUBLE CD23 TRAINING, A PROCEDURE FOR ITS PREPARATION, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION AND INTERMEDIARY COMPOUNDS - Google Patents
INHIBITORS OF THE HUMAN SOLUBLE CD23 TRAINING, A PROCEDURE FOR ITS PREPARATION, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION AND INTERMEDIARY COMPOUNDSInfo
- Publication number
- AR005472A1 AR005472A1 ARP970100153A ARP970100153A AR005472A1 AR 005472 A1 AR005472 A1 AR 005472A1 AR P970100153 A ARP970100153 A AR P970100153A AR P970100153 A ARP970100153 A AR P970100153A AR 005472 A1 AR005472 A1 AR 005472A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitors
- manufacture
- preparation
- pharmaceutical composition
- training
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Los compuestos de fórmula (1) en la cual R y R3 son cado uno independientemente hidrógeno, alquilo, alquenilo, alquinilo o arilo; R1 esarilmetilo; y R2 es alquilo, alquenilo, arilo, cicloalquilo o cicloalquenilo, y sus derivados farmacéuticamente aceptables, son útiles en el tratamiento y laprofilaxis de trastornos en los cuales está implicada la superproducción de sCD23. Inhibidores de la formación CD23 humana soluble, un procedimiento parasu preparación, el uso de los mismospara la manufactura de un mediamento, composición farmacéutica y compuestos intermediarios.Compounds of formula (1) in which R and R3 are each independently hydrogen, alkyl, alkenyl, alkynyl or aryl; R1 isarylmethyl; and R2 is alkyl, alkenyl, aryl, cycloalkyl or cycloalkenyl, and their pharmaceutically acceptable derivatives are useful in the treatment and prophylaxis of disorders in which the overproduction of sCD23 is implicated. Inhibitors of soluble human CD23 formation, a process for their preparation, their use for the manufacture of a drug, pharmaceutical composition and intermediate compounds.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9601041.8A GB9601041D0 (en) | 1996-01-17 | 1996-01-17 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR005472A1 true AR005472A1 (en) | 1999-06-23 |
Family
ID=10787226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970100153A AR005472A1 (en) | 1996-01-17 | 1997-01-15 | INHIBITORS OF THE HUMAN SOLUBLE CD23 TRAINING, A PROCEDURE FOR ITS PREPARATION, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION AND INTERMEDIARY COMPOUNDS |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0912545A1 (en) |
| JP (1) | JP2000503312A (en) |
| KR (1) | KR19990077325A (en) |
| CN (1) | CN1213368A (en) |
| AR (1) | AR005472A1 (en) |
| AU (1) | AU725056B2 (en) |
| BR (1) | BR9707024A (en) |
| CA (1) | CA2242913A1 (en) |
| CZ (1) | CZ222498A3 (en) |
| GB (1) | GB9601041D0 (en) |
| HU (1) | HUP9901022A3 (en) |
| IL (1) | IL125381A0 (en) |
| NO (1) | NO983283L (en) |
| NZ (1) | NZ326352A (en) |
| PL (1) | PL327820A1 (en) |
| TR (1) | TR199801380T2 (en) |
| TW (1) | TW462967B (en) |
| WO (1) | WO1997026257A1 (en) |
| ZA (1) | ZA97345B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| GB9609795D0 (en) * | 1996-05-10 | 1996-07-17 | Smithkline Beecham Plc | Novel compounds |
| WO2000040713A1 (en) * | 1999-01-06 | 2000-07-13 | Mcmaster University | Method of preventing immune and hypersensitivity reactions |
| GB9922825D0 (en) * | 1999-09-25 | 1999-11-24 | Smithkline Beecham Biolog | Medical use |
| AU2001271068A1 (en) * | 2000-07-18 | 2002-01-30 | Chugai Seiyaku Kabushiki Kaisha | Matrix metalloprotease inhibitors |
| CA2473754C (en) * | 2002-01-28 | 2012-04-10 | Aimsco Limited | Treatment of ms with goat serum |
| EP1787986A4 (en) | 2004-08-10 | 2007-08-22 | Shizuoka Coffein Co Ltd | Hydroxamic acid derivative and medicine containing the same as active ingredient |
| KR100844277B1 (en) * | 2005-04-29 | 2008-07-07 | (주)아모레퍼시픽 | A hydroxamic acid derivative and the preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4743587A (en) * | 1985-09-10 | 1988-05-10 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
| GB8827305D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| GB9504084D0 (en) * | 1995-03-01 | 1995-04-19 | British Biotech Pharm | Synthesis of carboxylic and hydroxamic acid derivatives |
-
1996
- 1996-01-17 GB GBGB9601041.8A patent/GB9601041D0/en active Pending
-
1997
- 1997-01-14 KR KR1019980705472A patent/KR19990077325A/en not_active Application Discontinuation
- 1997-01-14 HU HU9901022A patent/HUP9901022A3/en unknown
- 1997-01-14 BR BR9707024A patent/BR9707024A/en unknown
- 1997-01-14 PL PL97327820A patent/PL327820A1/en unknown
- 1997-01-14 WO PCT/EP1997/000196 patent/WO1997026257A1/en not_active Application Discontinuation
- 1997-01-14 CA CA002242913A patent/CA2242913A1/en not_active Abandoned
- 1997-01-14 EP EP97901055A patent/EP0912545A1/en not_active Withdrawn
- 1997-01-14 JP JP9525693A patent/JP2000503312A/en active Pending
- 1997-01-14 CN CN97192982A patent/CN1213368A/en active Pending
- 1997-01-14 CZ CZ982224A patent/CZ222498A3/en unknown
- 1997-01-14 TR TR1998/01380T patent/TR199801380T2/en unknown
- 1997-01-14 NZ NZ326352A patent/NZ326352A/en unknown
- 1997-01-14 AU AU14436/97A patent/AU725056B2/en not_active Ceased
- 1997-01-14 IL IL12538197A patent/IL125381A0/en unknown
- 1997-01-15 AR ARP970100153A patent/AR005472A1/en unknown
- 1997-01-16 ZA ZA97345A patent/ZA97345B/en unknown
- 1997-01-30 TW TW086101017A patent/TW462967B/en active
-
1998
- 1998-07-16 NO NO983283A patent/NO983283L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU1443697A (en) | 1997-08-11 |
| JP2000503312A (en) | 2000-03-21 |
| TR199801380T2 (en) | 1998-10-21 |
| WO1997026257A1 (en) | 1997-07-24 |
| IL125381A0 (en) | 1999-03-12 |
| NO983283L (en) | 1998-09-16 |
| HUP9901022A2 (en) | 1999-07-28 |
| AU725056B2 (en) | 2000-10-05 |
| NZ326352A (en) | 2000-03-27 |
| EP0912545A1 (en) | 1999-05-06 |
| CN1213368A (en) | 1999-04-07 |
| NO983283D0 (en) | 1998-07-16 |
| KR19990077325A (en) | 1999-10-25 |
| TW462967B (en) | 2001-11-11 |
| HUP9901022A3 (en) | 2001-11-28 |
| BR9707024A (en) | 1999-07-20 |
| CA2242913A1 (en) | 1997-07-24 |
| PL327820A1 (en) | 1999-01-04 |
| CZ222498A3 (en) | 1999-03-17 |
| GB9601041D0 (en) | 1996-03-20 |
| ZA97345B (en) | 1998-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0204246A2 (en) | Novel thiazolo[4,5-d]pyrimidine compounds, process for their preparation, pharmaceutical compositions containing them and their use | |
| CO4810373A1 (en) | ARYL-CONDENSED AZAPOLYCLIC COMPOUNDS | |
| MX9300786A (en) | HYPOLIPIDAEMIC COMPOUNDS. | |
| AR007828A1 (en) | COMPOUNDS DERIVED FROM PIRIDILPIRROL, PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
| NZ514487A (en) | Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands | |
| ATE246190T1 (en) | HETEROCYCLIC COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE IN THE TREATMENT OF DIABETIS AND RELATED DISEASES | |
| MX9305379A (en) | NEW AMINO ACID DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATION CONTAINING THEM. | |
| AR008853A1 (en) | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS, THEIR USE IN THE MANUFACTURE OF MEDICINES, TREATMENT METHOD, PHARMACEUTICAL COMPOSITION, INTERMEDIATE COMPOUNDS AND PROCESS FOR THE MANUFACTURE OF SUCH COMPOUNDS | |
| HN1998000074A (en) | DERIVATIVES FROM MACROLIDES C-4 SUBSTITUTED | |
| AR012294A1 (en) | DERIVATIVES OF SULFONAMIDE, A PROCEDURE FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A MEDICINAL PRODUCT. | |
| HUP9802762A2 (en) | Diphenylmethylene piperidine derivatives, pharmaceutical compositions containing them, process for producing them and their use | |
| HUP0402422A2 (en) | Deuterated substituted pyrazolylbenzylsulfonamides pharmaceutical compositions containing them and use thereof | |
| AU4483000A (en) | Inhibitors of c-jun n-terminal kinases (jnk) | |
| SE9702564D0 (en) | New compounds | |
| AR013079A1 (en) | SUBSTITUTED DERIVATIVES OF TETRAHIDROFURANO-3-ONAS, TETRAHIDROPIRANO-3- ONAS AND TETRAHIDROTIOFEN-3-ONAS, A PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION OF A MEDICINAL PRODUCT USEFUL AS INTERMEDIATE PROTEIN INHIBITORS | |
| ES2141957T3 (en) | USE OF RALOXIFENE AND ITS ANALOGS FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF VIRAL DISEASES. | |
| ES2123652T3 (en) | 7- (2-AMINOETIL) -BENZOTIAZOLONAS. | |
| ES2087625T3 (en) | SUBSTITUTED CYCLOHEXANE DERIVATIVES, PROCEDURE FOR THE PREPARATION AND USE OF THE COMPOUNDS FOR THE TREATMENT OF DISEASES. | |
| HUP0001922A2 (en) | Pyrazolo[4,3-c]-pyridine derivatives, pharmaceutical compositions thereof against insulin resistance, intermediates and process for their preparation | |
| ES2101858T3 (en) | GENESERINE DERIVATIVES AS CHOLINESTERASE INHIBITORS. | |
| UY28377A1 (en) | THERAPEUTIC AGENTS | |
| AR007108A1 (en) | ANTI-TUMOR AND ANTIVIRAL RENTAL AGENTS, PROCEDURE FOR THEIR PREPARATION, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH AGENTS. | |
| AR005472A1 (en) | INHIBITORS OF THE HUMAN SOLUBLE CD23 TRAINING, A PROCEDURE FOR ITS PREPARATION, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION AND INTERMEDIARY COMPOUNDS | |
| SE0101322D0 (en) | Novel compounds | |
| YU64400A (en) | Aryl fused azapolycyclic compounds |